| 產品名稱 | TRAMP-C1 |
|---|---|
| 商品貨號 | B162462 |
| Organism | Mus musculus, transgenic, mouse, transgenic |
| Tissue | prostate |
| Cell Type | epithelial |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 2 [Cells contain SV40 DNA viral sequences]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | adenocarcinoma |
| Age | adult |
| Gender | male |
| Strain | C57BL/6-TgN(TRAMP)8247Ng |
| Applications | The cell lines can be used in studies to elucidate molecular mechanisms associated with the initiation, progression and metastasis of prostate cancer. They are also a useful tool for gene/drug discovery. |
| Storage Conditions | liquid nitrogen vapor phase |
| Derivation | The TRAMP-C1 (ATCC- CRL-2730), TRAMP- C2 (ATCC-CRL-2731) and TRAMP-C3 (ATCC CRL-2732) cell lines were derived in 1996 from a heterogeneous 32 week primary tumor in the prostate of a PB-Tag C57BL/6 (TRAMP) mouse. |
| Clinical Data | male |
| Receptor Expression | androgen receptor, expressed |
| Genes Expressed | E-cadherin, cytokeratin |
| Cellular Products | E-cadherin cytokeratin |
| Tumorigenic | Yes |
| Effects | Yes, C57BL/6 hosts No, soft agar |
| Comments | TRAMP is a transgenic line of C57BL/6 mice harboring a construct comprised of the minimal -426/+28 rat probasin promoter (426 base pairs of the rat probasin (PB) gene promoter and 28 base pairs of 5'-untranslated region) to target expression of the SV40 large T antigen to prostatic epithelium. Neither the cells grown in culture, nor the tumors arising from the cells in vivo, express SV40 T antigen (Tag). TRAMP-C1 and TRAMP-C2 are tumorigenic when grafted into syngeneic C57BL/6 hosts. However, TRAMP-C3 grows readily in vitro, but does not form tumors. These cell lines represent various stages of cellular transformation and progression to androgen-independent metastatic disease that can be manipulated in vitro. |
| Complete Growth Medium | Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 0.005 mg/ml bovine insulin and 10 nM dehydroisoandrosterone, 90%; fetal bovine serum, 5%; Nu-Serum IV, 5%.
|
| Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: 1:6 to 1:10 Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 13 in Culture of Animal Cells: a Manual of Basic Technique by R. Ian Freshney, 5th edition, published by Wiley-Liss N.Y., 2005. |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| Population Doubling Time | 25 hrs |
| Name of Depositor | N Greenberg |
| Deposited As | mouse, transgenic |
| Year of Origin | 1996 |
| References | Hurwitz AA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94: 8099-8103, 1997. PubMed: 9223321 Foster BA, et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57: 3325-3330, 1997. PubMed: 9269988 Greenberg NM, et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443, 1995. PubMed: 7724580 Greenberg NM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8: 230-239, 1994. PubMed: 8170479 Gingrich JR, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56: 4096-4102, 1996. PubMed: 8797572 Greenberg NM. Transgenic models for prostate cancer research. Urol. Oncol. 2: 119-122, 1996. Gingrich JR, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57: 4687-4691, 1997. PubMed: 9354422 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
